Cargando…

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update

Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeven, Yannick, Quatannens, Delphine, Trinh, Xuan Bich, Wouters, An, Smits, Evelien L.J., Lardon, Filip, De Waele, Jorrit, van Dam, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917788/
https://www.ncbi.nlm.nih.gov/pubmed/33670397
http://dx.doi.org/10.3390/ijms22041807
_version_ 1783657777699225600
author Verhoeven, Yannick
Quatannens, Delphine
Trinh, Xuan Bich
Wouters, An
Smits, Evelien L.J.
Lardon, Filip
De Waele, Jorrit
van Dam, Peter A.
author_facet Verhoeven, Yannick
Quatannens, Delphine
Trinh, Xuan Bich
Wouters, An
Smits, Evelien L.J.
Lardon, Filip
De Waele, Jorrit
van Dam, Peter A.
author_sort Verhoeven, Yannick
collection PubMed
description Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use.
format Online
Article
Text
id pubmed-7917788
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79177882021-03-02 Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update Verhoeven, Yannick Quatannens, Delphine Trinh, Xuan Bich Wouters, An Smits, Evelien L.J. Lardon, Filip De Waele, Jorrit van Dam, Peter A. Int J Mol Sci Review Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients, but progress in new systemic treatment modalities has been slow in the last years. Especially for patients with advanced disease this is discouraging, as their prognosis remains very poor. The pathogen-induced nature, the considerable mutational load, the involvement of genes regulating the immune response, and the high grade of immune infiltration, suggest that immunotherapy might be a promising strategy to treat cervical cancer. In this literature review, we focus on the use of PD-1 blocking therapy in cervical cancer, pembrolizumab in particular, as it is the only approved immunotherapy for this disease. We discuss why it has great clinical potential, how it opens doors for personalized treatment in cervical cancer, and which trials are aiming to expand its clinical use. MDPI 2021-02-11 /pmc/articles/PMC7917788/ /pubmed/33670397 http://dx.doi.org/10.3390/ijms22041807 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Verhoeven, Yannick
Quatannens, Delphine
Trinh, Xuan Bich
Wouters, An
Smits, Evelien L.J.
Lardon, Filip
De Waele, Jorrit
van Dam, Peter A.
Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
title Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
title_full Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
title_fullStr Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
title_full_unstemmed Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
title_short Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
title_sort targeting the pd-1 axis with pembrolizumab for recurrent or metastatic cancer of the uterine cervix: a brief update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917788/
https://www.ncbi.nlm.nih.gov/pubmed/33670397
http://dx.doi.org/10.3390/ijms22041807
work_keys_str_mv AT verhoevenyannick targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT quatannensdelphine targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT trinhxuanbich targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT woutersan targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT smitsevelienlj targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT lardonfilip targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT dewaelejorrit targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate
AT vandampetera targetingthepd1axiswithpembrolizumabforrecurrentormetastaticcanceroftheuterinecervixabriefupdate